Skip to main content
Log in

TRUMP DECEIVING THAT TARIFFS WILL FORCE MAKERS TO BUILD US PLANT, THE HISTORY OF TARIFFS SHOWS THIS IS NOT THE CASE...HIS ADVICE HAS TOLD HIM THAT

    Administrator
    By Administrator

    [OPINION]

    A Drug Company will not build plant under duress in a non competitive economy as drugs only have a limited marketing cycle before they are no longer in patent, a company will more likely pass on tariffs or licensing patent, avoiding investment. Trump knows this but is deceiving.

    [AI PERSPECTIVE] 

    A company could be a "maker of patent drugs" by being the API originator of the drug, holding the primary patent for its active pharmaceutical ingredient, or by holding secondary patents for modifications to the original drug, a practice known as "evergreening".

     

     Another maker could also be a generic drug manufacturer that produces bioequivalent versions of a drug after its primary patent has expired, or a non-originator patent holder such as a university or a company that holds patents associated with the drug but not for the drug itself.  Here are the different ways another maker can be involved with patent drugs: 

    Original Patent Holder: The company that obtains the initial patent for the active pharmaceutical ingredient (API) of a new drug. 

     

     Secondary Patent Holder (Evergreening): A company that obtains additional patents for minor modifications to an existing drug, such as new dosages, delivery methods, or combinations, to extend market exclusivity and delay generic competition.  

    Generic Manufacturer: A company that develops and sells generic versions of a branded drug once its primary patent protection has expired. Generic drugs are bioequivalent to the original drug but are typically offered at a lower price. 

     Non-Originator Patent Holder: This can include entities like generic drug manufacturers or universities that hold patents associated with a drug, such as those related to manufacturing processes, but not the original API.  

    Other Drug Originators: A company that holds patents associated with a high-cost drug that was originally developed by another company.  Innovator/Branded Drug Manufacturer: A company that focuses on developing new drugs and holds the patents for these original discoveries.